At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 75 enrolled
Drug / intervention
SKI-606 (Bosutinib)drug
Likely dose
SKI-606 (Bosutinib) 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study Of SKI-606 In Subjects With Advanced Or Metastatic Breast Cancer
In Brief
A Phase 2 clinical trial evaluating SKI-606 (Bosutinib) for Breast Neoplasms and Neoplasm Metastasis. Completed, enrolled 75 participants across 15 sites in 8 countries.
Detailed Summary
The purpose of this study is to determine if SKI-606 (Bosutinib) is effective in the treatment of advanced or metastatic breast cancer. Patients must have current Stage IIIB, IIIC or IV breast cancer and have progressed after 1 to 3 prior chemotherapy regimens.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Neoplasms, Neoplasm Metastasis
CountriesAustralia, France, Hong Kong, Malta, Poland, Russia, Ukraine, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 2006
Enrollment StartMay 2006
Primary CompletionFeb 2009
TodayJul 2026
First PostedApr 27, 2006
Enrollment StartMay 1, 2006
Primary CompletionFeb 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 20.2 years ago
Interventions
SKI-606 (Bosutinib)drug
SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.